Brought to you by 
Hospira gets exclusive rights to Kiadis's ATIR
19 Apr 2021
Executive Summary
Kiadis Pharma (oncology) has granted Hospira Inc. exclusive rights to sell its ATIR blood cancer product in Europe, the Middle East, Africa, Australia, Japan, and parts of Asia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hospira gets exclusive rights to Kiadis's ATIR
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice